Novartis and Momenta alleged that the lack of information about the molecular weight of the molecules rendered the patents unenforceable, according to a note to investors by Sanford C.
Also publicly available are databases loaded with information about many of the proteins found in the human body, and what sorts of molecules they tend to interact with.